Drug intelligence / Profile preview

gdc-0980 + paclitaxel + carboplatin

Development stage: Phase 1
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral (GDC-0980/apitolisib), Intravenous (paclitaxel, Carboplatin)

Overview

GDC-0980 + paclitaxel + carboplatin is a combination regimen involving GDC-0980 (apitolisib), a **dual inhibitor of class I PI3K and mTOR kinases**[3][5], with paclitaxel, a microtubule-stabilizing agent, and carboplatin, a platinum-based chemotherapy drug. GDC-0980 acts as a targeted therapy inhibiting both PI3K and mTOR pathways, disrupting aberrant signaling important in cancer cell growth and survival[3][5]. Paclitaxel and carboplatin are standard cytotoxic agents used in various cancers, notably ovarian, endometrial, and non-small-cell lung cancer, providing antineoplastic activity through microtubule stabilization (paclitaxel) and DNA crosslinking/platinum adduct formation (carboplatin)[2][4][6][8]. This combination is evaluated for its synergistic antitumor activity in patients with advanced solid malignancies.

Brand names: Taxol (paclitaxel)Paraplatin (carboplatin)
Other names: apitolisib + paclitaxel + carboplatin

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)DNAmTOR (Mammalian target of rapamycin kinase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on gdc-0980 + paclitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gdc-0980 + paclitaxel + carboplatin.